Imperial College London
Portrait Picture

Dr Nick Powell

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Gastroenterology
 
 
 
//

Contact

 

nicholas.powell

 
 
//

Assistant

 

Mrs Heather Bones +44 (0)20 7594 2429

 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Digby-Bell:2020:10.1038/s41575-019-0228-5,
author = {Digby-Bell, JL and Atreya, R and Monteleone, G and Powell, N},
doi = {10.1038/s41575-019-0228-5},
journal = {Nature Reviews Gastroenterology and Hepatology},
pages = {9--20},
title = {Interrogating host immunity to predict treatment response in inflammatory bowel disease},
url = {http://dx.doi.org/10.1038/s41575-019-0228-5},
volume = {17},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - IBD treatment is undergoing a transformation with an expanding repertoire of drugs targeting different aspects of the immune response. Three novel classes of drugs have emerged in the past decade that target leukocyte trafficking to the gut (vedolizumab), neutralize key cytokines with antibodies (ustekinumab) and inhibit cytokine signalling pathways (tofacitinib). In advanced development are other drugs for IBD, including therapies targeting other cytokines such as IL-23 and IL-6. However, all agents tested so far are hampered by primary and secondary loss of response, so it is desirable to develop personalized strategies to identify which patients should be treated with which drugs. Stratification of patients with IBD by clinical parameters alone lacks sensitivity, and alternative modalities are now needed to deliver precision medicine in IBD. High-resolution profiling of immune response networks in individual patients is a promising approach and different technical platforms, including in vivo real-time molecular endoscopy, tissue transcriptomics and germline genetics, are promising tools to help predict responses to specific therapies. However, important challenges remain regarding the clinical utility of these technologies, including their scalability and accessibility. This Review focuses on unravelling some of the complexity of mucosal immune responses in IBD pathogenesis and how current and emerging analytical platforms might be harnessed to effectively stratify and individualise IBD therapy.
AU  - Digby-Bell,JL
AU  - Atreya,R
AU  - Monteleone,G
AU  - Powell,N
DO  - 10.1038/s41575-019-0228-5
EP  - 20
PY  - 2020///
SN  - 1759-5045
SP  - 9
TI  - Interrogating host immunity to predict treatment response in inflammatory bowel disease
T2  - Nature Reviews Gastroenterology and Hepatology
UR  - http://dx.doi.org/10.1038/s41575-019-0228-5
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000504707500007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/76167
VL  - 17
ER  -
Download